797792-92-8Relevant academic research and scientific papers
Understanding the mechanism of action of pyrrolo[3,2-: B] quinoxaline-derivatives as kinase inhibitors
Bernasconi, Elena,Bertoni, Francesco,Caflisch, Amedeo,Cascione, Luciano,Dong, Jing,Gaudio, Eugenio,Jessen-Trefzer, Claudia,Nevado, Cristina,Pachmayr, Johanna,Sartori, Giulio,Spiliotopoulos, Dimitrios,Tarantelli, Chiara,Unzue, Andrea,Zahler, Stefan,Zhao, Hongtao,?led?, Pawe?
, p. 665 - 675 (2020)
The X-ray structure of the catalytic domain of the EphA3 tyrosine kinase in complex with a previously reported type II inhibitor was used to design two novel quinoxaline derivatives, inspired by kinase inhibitors that have reached clinical development. Th
2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates
-
Paragraph 0171; 0187, (2015/11/16)
The invention relates to compound characterized by a general formula (1), wherein n of R1n is 0, 1, 2, 3 or 4, in particular n of R1n is 0 or 1, and each R1 independently from any other R1
Nitrogenous heterocyclic compounds and medical use thereof
-
Page/Page column 38, (2010/11/25)
The present invention relates to a compound represented by formula (I): (wherein all the symbols have the same meanings as defined in the above description) and a production method and use thereof. The compounds represented by formula (I), or its salt, N-oxide or solvate, or a prodrug thereof have p38 MAP kinase inhibitory activity, and are useful in the prevention and/or treatment of those diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokine or chemokine, or by over response thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular disease, central nervous system diseases, and the like.
